

1/6

Age at informed consent (years)	Mean (SD)	71.4 (8.53)
	Median (range)	72.0 (57–86)
Age group, n (%)	< 65 years	7 (25.9)
	≥ 65 years	20 (74.1)
Race, n (%)	Black or African American	4 (14.8)
	White	23 (85.2)
Country, n (%)	Canada	12 (44.4)
	United States	15 (55.6)
PSA at baseline, median (range)		22 (0.3–701.0)
ECOG performance status, n (%)	0	16 (59.3)
	1	11 (40.7)
Prior taxane treatment for HSPC, n (%)	Yes	6 (22.2)
	No	21 (77.8)
Prior bisphosphonate treatment, n (%)	Yes	14 (51.9)
	No	13 (48.1)
Receiving opioids for cancer-related pain, n (%)	No	27 (100.0)
Progressed on prior ARPI therapy, n (%)	Yes	27 (100.0)
	- Enzalutamide	12 (44.4)
	- Abiraterone	12 (44.4)
	- Apalutamide	2 (7.4)
	- Darolutamide	1 (3.7)
Metastatic status on prior ARPI therapy, n (%)	M0	11 (40.7)
	M1	16 (59.3)

FIG. 1

2/6

Number (%) of participants by number of ^{177}Lu -PNT2002 cycles	
1 cycle	3 (11.1)
2 cycles	3 (11.1)
3 cycles	2 (7.4)
4 cycles	19 (70.4)
Number of cycles of ^{177}Lu -PNT2002 out of the 4 planned	
(n=27)	
Mean (SD)	3.37 (1.079)
Median (range)	4.00 (1.0–4.0)
Dose per cycle (GBq) of ^{177}Lu -PNT2002	
(n=91)	
Mean (SD)	6.88 (0.268)
Median (range)	6.89 (6.2–7.5)

FIG. 2




FIG. 3




FIG. 4

	Any		Treatment-related*	
	# of pts	%	# of pts	%
TEAEs	25	92.6	14	51.9
TEAEs of CTCAE Grade 3 or higher	8	29.6	3	11.1
Serious adverse events (SAEs)	6	22.2	1	3.7
TEAEs leading to discontinuation of ¹⁷⁷ Lu-PNT2002	1	3.7	0	0.0
TEAEs leading to dose delay of ¹⁷⁷ Lu-PNT2002†	3	11.1	1	3.7
TEAEs leading to death‡	1	3.7	0	0.0

*Includes events assessed by the investigator as definitely, probably, or possibly related to treatment. †Reflects intended action at time of AE. ‡Fatal event of disseminated intravascular coagulation likely due to underlying malignancy, deemed unrelated to treatment by the investigator.

FIG. 5





FIG. 6C